TheStreet cut shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) from a b- rating to a c+ rating in a report published on Friday.

Other analysts have also issued reports about the company. Zacks Investment Research raised Alexion Pharmaceuticals from a hold rating to a buy rating and set a $144.00 price objective on the stock in a report on Tuesday, October 31st. Oppenheimer Holdings, Inc. raised Alexion Pharmaceuticals from a market perform rating to an outperform rating and set a $175.00 price objective on the stock in a report on Friday, July 28th. Royal Bank Of Canada initiated coverage on Alexion Pharmaceuticals in a report on Thursday, September 14th. They issued an outperform rating and a $161.00 price objective on the stock. Morgan Stanley reissued an overweight rating and issued a $153.00 price objective (up from $141.00) on shares of Alexion Pharmaceuticals in a report on Friday, July 28th. Finally, BidaskClub raised Alexion Pharmaceuticals from a buy rating to a strong-buy rating in a report on Saturday, August 5th. Six analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the stock. Alexion Pharmaceuticals currently has an average rating of Buy and a consensus price target of $154.01.

Shares of Alexion Pharmaceuticals (NASDAQ ALXN) traded down $1.72 during mid-day trading on Friday, reaching $113.45. The company had a trading volume of 1,620,000 shares, compared to its average volume of 2,289,474. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.51 and a current ratio of 2.96. The stock has a market capitalization of $25,350.00, a PE ratio of 23.55, a P/E/G ratio of 1.25 and a beta of 1.22. Alexion Pharmaceuticals has a 52 week low of $96.18 and a 52 week high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, beating the consensus estimate of $1.32 by $0.12. The company had revenue of $859.00 million during the quarter, compared to analysts’ expectations of $864.34 million. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. Alexion Pharmaceuticals’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period last year, the business earned $1.23 earnings per share. research analysts anticipate that Alexion Pharmaceuticals will post 4.81 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Alexion Pharmaceuticals, Inc. (ALXN) Downgraded to C+ at TheStreet” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.dailypolitical.com/2017/11/14/alexion-pharmaceuticals-inc-alxn-downgraded-to-c-at-thestreet.html.

In related news, Director Ann M. Veneman sold 835 shares of the business’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total value of $121,751.35. Following the sale, the director now owns 5,480 shares in the company, valued at approximately $799,038.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Julie O’neill sold 4,375 shares of the business’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $145.44, for a total value of $636,300.00. Following the completion of the sale, the executive vice president now owns 26,092 shares in the company, valued at approximately $3,794,820.48. The disclosure for this sale can be found here. Insiders sold 16,490 shares of company stock worth $2,337,251 in the last 90 days. Company insiders own 4.35% of the company’s stock.

Several hedge funds have recently bought and sold shares of ALXN. Fiduciary Trust Co. purchased a new stake in shares of Alexion Pharmaceuticals in the 2nd quarter valued at $111,000. Huntington National Bank raised its holdings in shares of Alexion Pharmaceuticals by 1,084.6% in the 2nd quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 987 shares during the period. Penserra Capital Management LLC raised its holdings in shares of Alexion Pharmaceuticals by 13.0% in the 2nd quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 144 shares during the period. Dupont Capital Management Corp purchased a new stake in shares of Alexion Pharmaceuticals in the 3rd quarter valued at $156,000. Finally, Acadian Asset Management LLC purchased a new stake in shares of Alexion Pharmaceuticals in the 2nd quarter valued at $160,000. Hedge funds and other institutional investors own 96.71% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.